A Phase 1/2 interventional study of 3D hypoxia-preconditioned UC-MSC group and 2D UC-MSC group in Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory and Severe Aplastic Anemia, sponsored by Chinese PLA General Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Chinese PLA General Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Anemia, Aplastic with a site in China — 40 open to participants now, 44 under way, 1 of them phase 3. Anemia, Aplastic · China.
Among the 89 studies in Anemia, Aplastic with a site in China, this one is the 44th largest by planned enrollment of the 74 interventional ones that give a count, is one of 9 that started in 2022, is one of 8 in phase 1/2, reaches primary completion later than 19 of the 43 other live ones, and was the 78th registered.
373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.
Browse Anemia, Aplastic studies →40 of the 89 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–40
Peking University People's Hospital · Sites in China
Ages 40–60
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.
This study: 6 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 36 · Phase 3 4 · Phase 4 16
First in 2002; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 52 across the 74 interventional studies, 300 across the 15 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 89 have an industry lead sponsor. The 10 most frequent:
Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.
Chinese PLA General Hospital has 1 study filed under Anemia, Aplastic — fewer than ten, so there is no comparison to draw.
9 of the studies in Anemia, Aplastic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06254560Institute of Hematology & Blood Diseases Hospital, ChinaRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | 2026-12-30 |
| NCT07299123Chinese PLA General HospitalPhase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA | 2026-12-31 |
| NCT07629947Peking University People's HospitalPeripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia | 2027-04-15 |
| NCT07552506Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin | 2027-05-01 |
| NCT06964971The First Affiliated Hospital of Zhejiang Chinese Medical UniversityTreatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study | 2027-05-20 |
Add all 9 to your calendar (.ics) → With an account.
Among the 89 studies in Anemia, Aplastic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy and Safety of Sequential Infusion of Hypoxic 3D-Cultured Umbilical Cord Mesenchymal Stem Cells in Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: A Multicenter, Randomized, Phase 1 Trial
The enrolled patients with an HLA-haploidentical relative for HSCT received the fludarabine (Flu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) conditioning regimen. For the patients with acute SAA (SAA-I), intravenous administration of 30 mg/(m2 day) of Flu and 500-800 mg/(m2 day) of Cy was performed from days -5 to -2, and 5μg/(kg day) of ATG was administered from days -4 to -1. For the patients with chronic SAA (SAA-II), the same treatment of ATG and Cy was applied as above with the supplement of 0.6 mg/(kg 6 h) of busulfan (BU) from days -8 to -5 prior to transplantation. Donor selection and hematopoietic stem cell mobilization and collection were conducted based on the consensus of The Chinese Society of Hematology regarding indications, conditioning regimens, and donor selection for allogeneic hematopoietic stem cell transplantation. On day 0, HSCs were infused intravenously. Both groups received 5 × 10⁵/kg UC-MSCs at 4 h before HSC infusion. The control group was transfused with conventional 2D-cultured UC-MSCs, whereas the experimental group received 3D hypoxia-preconditioned UC-MSCs. Standard GVHD prophylaxis consisted of mycophenolate mofetil, cyclosporine A, and methotrexate (MTX).
The inclusion criteria were (1) age 6 to 60 years; (2) diagnosis of SAA or very SAA according to the International Aplastic Anemia Study Group[21]; (3) without any severe pulmonary, cardiac, liver, or renal diseases or any active infection; and (4) adequate performance status ( score 0-2). Exclusion Criteria:(1)Age 6 years or > 60 years; (2)Failure to meet the IAASG-defined diagnosis of SAA/vSAA, or confirmed (3)Fanconi anemia, congenital aplastic anemia (e.g., dyskeratosis congenita, Diamond-Blackfan anemia); (4)Presence of severe pulmonary, cardiac, hepatic, or renal insufficiency; Uncontrolled active infection; (5)Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 3.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 3D hypoxia-preconditioned UC-MSC group
Drug: 2D UC-MSC group
5 × 10⁵/kg 3D hypoxia-preconditioned UC-MSCs at 4 h before HSC infusion
5 × 10⁵/kg 2D UC-MSCs at 4 h before HSC infusion
Adverse events
Time frame: The incidence and severity of adverse events (AEs) within the first 150 days after haplo-HSCT
acute GVHD
Time frame: 100days after HSCT
chronic GVHD
Time frame: 1 years after HSCT
Surivial
Time frame: 1 year after HSCT
Rates of relapse
Time frame: UP to 2 years after HSCT
The implantation
The implantation rate and implantation time.
Time frame: Up to 4 weeks after HSCT
Plan to share: Yes — Treatment effect
Supporting information: Study protocol
Time frame: 2025/10/1-2027/1/1
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital →